Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world

Conclusion: Pazopanib was found a feasible treatment option for M-STS in India with internationally comparable outcomes. However, significant patients required dose modifications, and median tolerated dose was lower than the standard 800 mg dose. This novel finding merits confirmation in larger cohorts for reproducibility.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research